Update on the febrile seizure signal after 2010 2011 influenza vaccine
Download
1 / 15

Update on the febrile seizure signal after 2010-2011 influenza vaccine - PowerPoint PPT Presentation


  • 232 Views
  • Uploaded on

Update on the febrile seizure signal after 2010-2011 influenza vaccine. David Martin, MD, MPH Pharmacovigilance Branch Division of Epidemiology Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research February 25, 2011. Background.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Update on the febrile seizure signal after 2010-2011 influenza vaccine' - lilia


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Update on the febrile seizure signal after 2010 2011 influenza vaccine l.jpg

Update on the febrile seizure signal after 2010-2011 influenza vaccine

David Martin, MD, MPH

Pharmacovigilance Branch

Division of Epidemiology

Office of Biostatistics and Epidemiology

Center for Biologics Evaluation and Research

February 25, 2011


Background l.jpg
Background influenza vaccine

  • Febrile seizures: seizures that occur in febrile children who do not have an intracranial infection, metabolic disturbance, or history of afebrile seizures1,2

    • Affects 2-5% of young children in the United States1

    • Usually occurs at ages 6-60 months

    • Peak age 14-18 months

  • Australia suspended 2010 seasonal trivalent influenza vaccination for all children < 5 years old in April 2010

    • In the US, the CSL influenza vaccine (Afluria) is not recommended for children <9 years for the 2010-11 influenza season due to these findings3

    • Enhanced monitoring for febrile seizures was conducted by FDA and CDC in the 2010-11 season

1AAP. Pediatrics. 2008;121:1281-6. 2Johnston M. Nelson Textbook of Pediatrics. 2007.

3http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5931a4.htm


Framework for vaccine safety monitoring at the fda center for biologics evaluation and research l.jpg
Framework for Vaccine Safety Monitoring at the FDA Center for Biologics Evaluation and Research

Safety data from clinical trials

Periodic Reporting by sponsors

VAERS

Othersources

Signaldetection

Activesurveillance

Signal strengthening

Signalvalidation

Signal evaluation: hypothesis testing in a formal pharmacoepidemiologic study

In order to detect new unexpected safety signals, CBER medical officers rely on VAERS, safety data from clinical trials, periodic reporting by sponsors, and other sources such as the medical literature. These safety signals then become new outcomes of interest which are the subject of active surveillance activities. If the signals are strengthened and validated in these systems, then they can be tested in formal epidemiologic studies.


Product event disproportionality in vaers l.jpg
Product - event disproportionality in VAERS for Biologics Evaluation and Research

  • Statistic called Empirical Bayesian Geometric Mean (EBGM) quantifies disproportional reporting in the VAERS database

    • FDA ranks influenza product brand name-event combinations by the lower 5% bound (EB05) of the confidence interval surrounding the EBGM

      • More specific than EBGM

      • Limitations of VAERS apply: EBGMs and EB05s do not demonstrate causality


Fluzone febrile seizure signal l.jpg
Fluzone – febrile seizure signal for Biologics Evaluation and Research

  • FDA VAERS data mining signaled for the combination of Fluzone and the coding term febrile convulsion in December 2010

    • EB05>2 with no stratification of the database

    • Signal strengthened in the 0-18 months age stratum

    • Signal has persisted into January 2011

    • No interaction with other vaccines

    • No other independent vaccine product - febrile convulsion findings to date

  • FDA and CDC reviewed available VAERS data mining and VSD rapid cycle analysis findings

  • FDA and VAERS public communication issued on January 20, 2011

    • http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ucm240037.htm

    • http://vaers.hhs.gov/resources/updates


Signal strengthening in vsd l.jpg
Signal strengthening in VSD for Biologics Evaluation and Research

  • Prospective surveillance for febrile seizures in Influenza RCA

    • Signal identified

  • Prospective surveillance for febrile seizures in Pneumococcal Conjugate RCA for PCV13

    • No signal

  • Joint signal evaluation in Influenza and Pneumococcal RCA

    • Signal with concomitant administration

Grace Lee, ACIP presentation, 2/23/2011


Seizures definition in influenza rca 2010 11 l.jpg
Seizures Definition in Influenza RCA, 2010-11 for Biologics Evaluation and Research

  • Age group

    • 6 months – 4 years

    • 5 – 17 years

  • ICD9 codes

    • 780.3* Convulsions

  • Setting

    • Inpatient or ED only

  • Time period

    • Risk Window 0-1 days (based on findings from Australia)

    • Comparison Window 14-15 days

  • First in 6 months

7

Grace Lee, ACIP presentation, 2/23/2011


Self controlled rapid cycle analysis for 780 3 and tiv 6 59 mo l.jpg
Self-Controlled Rapid Cycle Analysis for 780.3* and TIV, 6-59 mo

The VSD primary analysis signaled on December 26, 2010 when the log likelihood ratio crossed the critical value.

8

Grace Lee, ACIP presentation, 2/23/2011


Concomitant vaccines among cases and vaccinees 6 23 months 2010 11 l.jpg
Concomitant Vaccines among Cases and Vaccinees 6-23 months, 2010-11

  • Seizure cases (N=20)

    • The majority concomitantly received either PCV13 (75%) and/or DTaP-containing vaccines (65%)

    • 11 children received both PCV13 and DTaP-containing vaccines

    • Only 15% of seizure cases received TIV only (i.e. no concomitant vaccines given)

  • TIV vaccinees (N=77,338)

    • Fewer TIV vaccine recipients concomitantly received PCV13 (36%) and/or DTaP-containing vaccines (34%)

    • 44% received TIV only

  • Of note, many children received both PCV13 and DTaP simultaneously with TIV, but only PCV13 was new this season

Grace Lee, ACIP presentation, 2/23/2011


Joint signal evaluation in influenza and pneumococcal rca l.jpg
Joint signal evaluation in Influenza and Pneumococcal RCA 2010-11

  • Design: Self-controlled

  • Seizures definition harmonized for influenza and PCV13 protocols:

    • Age group: 6-11mo; 12-23 mo; 24-59 mo

    • ICD9 codes: 780.3*

    • Setting: Inpt, ED

    • Risk window: 0-1 d

    • Comparison window: 14-20 d

    • First in 42 days

  • Attributable risk estimated from self-controlled design

Grace Lee, ACIP presentation, 2/23/2011


Joint febrile seizure evaluation findings in 12 23 month old children l.jpg
Joint febrile seizure evaluation findings in 12 – 23 month old children

08/05- 04/10

05/10 - 01/11

Attributable risk 61 (95% CI: +13 to +109) per 100,000 doses ~1 in 1,640 vaccinees for febrile seizures on days 0-1 following vaccination noted for TIV + PCV13* vaccinees for 12-23 month old children

Grace Lee, ACIP presentation, 2/23/2011

* +/- other non-TIV, non-PCV vaccines; assuming chart confirmation rate of 80%


Summary l.jpg
Summary old children

  • Biologic plausibility

    • Whole-cell pertussis vaccines, measles-containing vaccines and 2010 Southern Hemisphere CSL TIV have been associated with an increased risk of febrile seizures

    • DTaP was not associated with febrile seizures in a recent VSD analysis

  • VAERS data mining

    • Fluzone-febrile seizure signal

  • VSD prospective Historical and Self Controlled Analyses

    • Signal for 780.3* after TIV

    • No signal for 780.3* after PCV 13

  • VSD Joint Analysis

    • Signal for concomitant administration

    • Attributable risk ~ 61 per 100,000 doses


Next steps l.jpg
Next Steps old children

  • VSD investigation plans

    • Case ascertainment will continue until the end of influenza season

    • Chart review for all cases that received PCV13 and/or 2010-11 TIV on days 0-1 and 14-20 will be completed, and attributable risk estimates will be updated based on chart review

    • Role of other concomitant vaccines will be assessed

  • ACIP Working Groups

    • General Recommendations Working Group will consider additional information on febrile seizures following vaccination in coordination with other ACIP working groups as appropriate


Acknowledgements l.jpg
Acknowledgements old children

  • Frank DeStefano, MD, MPH

    • CDC Immunization Safety Office

  • Grace Lee, MD, MPH, Alison Tse, ScD & Hung-Fu Tseng, PhD, MPH on behalf of the Influenza and Pneumococcal Conjugate Vaccine RCA Working Groups

    • Harvard Pilgrim Health Care Institute and Southern California Kaiser Permanente

  • FDA CBER Pharmacovigilance Group


Joint fda cdc vaers descriptive analysis december 13 2010 l.jpg
Joint FDA/CDC VAERS descriptive analysis: December 13, 2010 old children

  • Forty-two febrile seizure cases after Fluzone

    • All recovered

    • Ten (24%) serious*; most hospitalized overnight and released

  • Vaccination to onset interval

    • Median: 10 hours

    • Range: 3 hours to 10 days

      • 86% occurred on the same day or day after administration

  • Concomitant vaccination reported in 27 (64%) of cases.

  • Medical history

    • Family history of seizure in 7 (17%) cases

    • Concurrent illness (URI or GI) in 6 (8%) of cases

    • Temperature elevation: 100.4 to 104°F

  • No apparent geographic or product lot clustering

*Regulatory definition: Any adverse experience occurring at any dose that results in any of the following outcomes: Death, a life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.


ad